Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 271-280 Newer>

BusinessWeek October 27, 2003 Gene G. Marcial	Imax: The Chase Is On? Rumors swirled last year that Imax was being pursued by Sony. Now, Sony may not be the only suitor. The pioneer in sound and projection for giant-screen theaters is a huge success, and movie studios are eager for its technology.
BusinessWeek October 27, 2003 Gene G. Marcial	Merchandise Floods Into TJX Stores Business has blossomed for TJX, the world's largest off-price retailer of soft goods, and inventory levels are improving.
BusinessWeek October 27, 2003 Gene G. Marcial	Checking In At Prime Hospitality No major street analyst is high on Prime Hospitality, which owns and franchises 240 hotels in the U.S. and the Virgin Islands, mainly AmeriSuites and Wellesley Inns & Suites. But Ben Segal, president of Winchester Capital Management, likes Prime for three reasons.
BusinessWeek October 20, 2003 Robert Barker	Newell Rubbermaid: Why It'll Bounce Back The dough is already coming in the door, and investors now are getting annual dividends of 84 cents a share. That's a 3.8% yield on a $22 stock that trades for 0.8 times sales and 13 times the Street's most bearish estimate of next year's earnings.
BusinessWeek October 20, 2003 David Henry	Earnings: What To Listen For This time out, revenue growth will have more impact than cost-cutting on stock prices.
BusinessWeek October 20, 2003 Gene G. Marcial	Boyd: More Buyout Bait? With the stock cheap and consolidation on the rise, casino operator Boyd Gaming may be takeover bait.
BusinessWeek October 20, 2003 Gene G. Marcial	Traffic Is Heavy At Radware Radware is a maker of Net traffic-management gear, operating in the shadow of giants Cisco Systems and and Nortel Networks. A look at Radware's strategy and stock.
BusinessWeek October 20, 2003 Gene G. Marcial	How Immune Response Targets AIDS Immune Response's Remune is aimed at slowing the advance of HIV and delaying the need for antiretroviral drugs, which have toxic effects. A look at the company's situation and its stock.
Knowledge@Wharton October 8, 2003	Biosciences: High Risk, High Reward, and the Potential for "Real Chaos" While bioscience researchers struggle to understand the workings of the human body, biotech managers and investors are searching for ways to better understand this complex and quickly evolving industry, according to Wharton faculty and lecturers.
BusinessWeek October 13, 2003 Anne Tergesen	A Closer Look at All Those Write-offs Once rare, they're now all too common. Here's how to weigh their hit to the bottom line.
<Older 271-280 Newer> Return to current articles.